Drugs / ICA07
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06821529 | May → Dec 2025 overdue | Parkinson disease | iCamuno Biotherapeutics Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICA07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06821529 ↗ |
| Action | Restore | “These cells will be transplanted directly into the striatum to restore dopamine-producing capacity.” NCT06821529 ↗ |
| Modality | Cell therapy | “Patients with Parkinson's disease will be treated with autologous induced pluripotent stem cell-derived dopamine progenitor cells (iPSC-DAPs).” NCT06821529 ↗ |
| Route | Other | “4 million iPSC-DAPs will be administrated into the putamen on each side of the brain” NCT06821529 ↗ |